嘉事堂药业股份有限公司 2020 年第三季度报告全文 嘉事堂药业股份有限公司 2020 年第三季度报告 2020-038 2020 年 10 月 1 嘉事堂药业股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人续文利、主管会计工作负责人续文利及会计机构负责人(会计主 管人员)王新侠声明：保证季度报告中财务报表的真实、准确、完整。 2 嘉事堂药业股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 14,024,460,513.39 | | 13,037,391,923.99 | 7.57% | | 归属于上市公司股东的净资产 | 3,556 ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 9,711,728,693.95, a decrease of 5.15% compared to CNY 10,238,752,103.42 in the same period last year[17]. - The net profit attributable to shareholders was CNY 135,661,448.28, down 35.81% from CNY 211,329,772.79 in the previous year[17]. - The net profit after deducting non-recurring gains and losses was CNY 130,794,996.51, a decline of 37.79% compared to CNY 210,247,138.71 in the same period last year[17]. - Basic and diluted earnings per share were both CNY 0.47, down 44.05% from CNY 0.84 in the same period last year[17]. - Total revenue for the reporting period was ¥9,711,728,693.95, a decrease of 5.15% compared to ¥10,238,752,103.42 in the same period last year[38]. - Net profit for the reporting period was ¥23,527.84, a decrease of 33.14% from ¥35,188.41 in the previous year[41]. - The company reported a total comprehensive income of 211.32 million yuan for the current period, compared to 140.55 million yuan in the previous year, indicating a significant increase of approximately 50.4%[157]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 175.70% to CNY 276,189,753.86, compared to CNY 100,178,639.62 in the previous year[17]. - The company experienced a significant increase in cash flow from operating activities, indicating improved operational efficiency despite declining profits[17]. - Cash received from operating activities increased by 63.70% to ¥18,260.00, compared to ¥11,154.85 in the previous year[41]. - The company maintained a focus on ensuring liquidity and operational stability through increased short-term financing amid the ongoing pandemic challenges[44]. - Cash flow from financing activities resulted in a net inflow of CNY 91,664,793.87, down from CNY 158,814,275.37 in the first half of 2019[151]. - The company reported a cash increase of CNY 36,013,903.99 for the period, compared to an increase of CNY 6,803,990.40 in the same period last year[151]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 13,234,305,346.85, an increase of 1.51% from CNY 13,037,391,923.99 at the end of the previous year[17]. - The total liabilities of the company were CNY 8,206,651,291.20, up from CNY 8,114,527,426.28[131]. - The company's equity remained stable with a share capital of CNY 291,707,120.00[131]. - The total amount of restricted cash decreased to RMB 86,750,052.69 from RMB 145,135,583.07 at the beginning of the year, reflecting a reduction in bank acceptance bill deposits[45]. - The total liabilities as of June 30, 2020, were CNY 2,262,299,766.27, down from CNY 2,357,572,518.43 at the end of 2019[136]. Business Operations and Strategy - The company optimized its business structure and product mix, enhancing supplier and product variety to improve business quality and reduce operational risks[26]. - The company accelerated cash collection through improved accounts receivable management and new financing explorations with financial institutions[26]. - High-value consumables sales continued to grow, supported by the company's brand advantages and collaboration with local medical device companies[26]. - The company maintained a balanced development of pharmaceutical and consumable businesses, enhancing its terminal network coverage and brand influence[29]. - The company adopted a strategy of "logistics supplementing devices" to quickly capture market share in the medical device sector, aligning with its strategic development plan[56]. Risk Management - The company has identified several risks including policy risk, strategic risk, operational risk, reputation risk, goodwill risk, and quality risk, and has implemented measures to mitigate these risks[66]. - The company emphasized risk control and compliance in operations, implementing strict quality management across all business processes[30]. - The company has a liquidity management strategy in place to ensure operational and debt repayment capabilities[66]. Investments and Acquisitions - The company has committed to investing RMB 22,749.21 million in a rapid drug delivery platform, with 100% of the funds allocated to the medical device logistics delivery network project[55]. - The company acquired 51% of Zhejiang Tonghan Biotechnology Co., Ltd. for RMB 43.76 million, with an outstanding payment of RMB 21.88 million as of June 30, 2020[102]. - The company purchased 51% of Zhejiang Jiashangyang Medical Technology Co., Ltd. for RMB 61.2 million, with an outstanding payment of RMB 30.6 million as of June 30, 2020[103]. - The acquisition of Chengdu Rongjin Pharmaceutical Trading Co., Ltd. for RMB 99.45 million was completed, with an outstanding payment of RMB 14.71 million as of June 30, 2020[104]. Social Responsibility and Community Engagement - The company reported a total of approximately 275,000 RMB invested in targeted poverty alleviation efforts during the first half of 2020[96]. - A direct donation of 2.3 million RMB was made through the Everbright Trust account, with an additional 200,000 RMB worth of anti-epidemic materials donated during the pandemic[96]. - The company has established a plan to prioritize hiring individuals from poverty-stricken counties during recruitment processes[98]. - The company is exploring partnerships with local health committees and public hospitals in targeted poverty alleviation counties to address medical supply challenges[98]. - The company acknowledges that the effectiveness of industrial poverty alleviation efforts is slow and requires ongoing commitment[99]. Corporate Governance - The financial report for the first half of 2020 was not audited[127]. - The financial statements were approved by the board of directors on August 25, 2020[170]. - The company has not encountered any major changes in the feasibility of its projects during the reporting period[58]. - The company has not faced any penalties or corrective actions during the reporting period[76].

Revenue and Profit - The company's revenue for Q1 2020 was ¥4,048,898,332.23, a decrease of 16.33% compared to ¥4,839,082,160.07 in the same period last year[7]. - Net profit attributable to shareholders was ¥50,980,357.36, down 48.37% from ¥98,737,958.33 year-on-year[7]. - Operating profit decreased by 47.41% to ¥113.43 million from ¥215.70 million, attributed to a decline in operating income due to the impact of COVID-19[16]. - Net profit fell by 49.09% to ¥81.72 million from ¥160.51 million, reflecting a decrease in total profit[17]. - The company reported a total profit of CNY 110,159,970.13 for the first quarter, down from CNY 215,695,714.74 in the previous year[39]. - The total comprehensive income for the first quarter was CNY 81,720,616.93, compared to CNY 160,508,634.40 in the same period last year[40]. Cash Flow - The net cash flow from operating activities was -¥199,951,828.35, representing a 298.45% increase in cash outflow compared to -¥50,182,482.22 in the previous year[7]. - Cash received related to operating activities rose by 116.96% to ¥119.04 million from ¥54.87 million, primarily due to pandemic-related material advance payments[18]. - Cash paid for operating activities decreased by 36.59% to ¥118.99 million from ¥187.65 million, reflecting a reduction in expenses due to lower income[18]. - The cash flow from operating activities was CNY 5,112,966,561.27, compared to CNY 5,595,773,448.56 in the previous period, showing a decrease in cash inflow[45]. - The net cash flow from investing activities was -9,501,502.41 CNY, compared to -2,482,735.59 CNY in the previous period, reflecting increased investment outflows[47]. - The total cash outflow for operating activities was 5,312,918,389.62 CNY, slightly down from 5,645,955,930.78 CNY in the previous period[47]. Assets and Liabilities - Total assets at the end of the reporting period were ¥12,555,887,801.49, a decline of 3.69% from ¥13,037,391,923.99 at the end of the previous year[7]. - Total liabilities decreased to CNY 7,536,359,140.19 from CNY 8,114,527,426.28, representing a reduction of 7.1%[31]. - The company's total equity increased to CNY 5,019,528,661.30 from CNY 4,922,864,497.71, marking an increase of 2.0%[32]. - The total non-current assets were CNY 1,301,022,352.19, slightly down from CNY 1,313,984,299.56, a decrease of 1.4%[32]. - The total assets of the company remained stable at approximately 13 billion CNY, with no significant adjustments reported[53]. Shareholder Information - The top ten shareholders hold a combined 58.36% of the company's shares, with the largest shareholder owning 14.36%[11]. - The company did not engage in any repurchase transactions during the reporting period[12]. - The company has a capital reserve of CNY 1,278,228,803.52 and a share capital of CNY 291,707,120.00[56]. Other Income and Expenses - The company reported a non-operating income of ¥5,449,204.73 from government subsidies, while incurring a loss of ¥102.56 from the disposal of non-current assets[8]. - The company reported a significant increase in other income, with other gains rising by 274.54% to ¥5.45 million from ¥1.45 million, mainly from tax refunds received by subsidiaries[16]. - Tax expenses decreased by 48.47% to ¥28.44 million from ¥55.19 million, mainly due to a reduction in total profit[17]. - Sales expenses for the first quarter were CNY 153,147,544.00, down from CNY 170,480,641.15 in the previous period[38]. Audit and Standards - The company has not undergone an audit for the first quarter report[57]. - The company has implemented new revenue and lease standards starting in 2020, with no retrospective adjustments to prior data[57].

Financial Performance - The company's operating revenue for 2019 was CNY 22,186,572,874.61, representing a 23.53% increase compared to CNY 17,959,885,466.92 in 2018[16] - The net profit attributable to shareholders for 2019 was CNY 375,957,176.99, which is a 14.75% increase from CNY 327,633,235.42 in the previous year[16] - The net cash flow from operating activities was CNY 293,114,556.75, a significant recovery from a negative cash flow of CNY -291,756,508.88 in 2018[16] - The total assets at the end of 2019 amounted to CNY 13,037,391,923.99, reflecting a 20.16% increase from CNY 10,850,365,413.55 at the end of 2018[17] - The net assets attributable to shareholders increased by 37.17% to CNY 3,425,524,154.59 from CNY 2,497,261,595.67 in 2018[17] - Basic earnings per share for 2019 were CNY 1.44, up 9.92% from CNY 1.31 in 2018[16] - The weighted average return on equity for 2019 was 13.38%, slightly down from 13.93% in the previous year[16] Revenue and Profit Distribution - The company plans to distribute a cash dividend of CNY 4 per 10 shares, based on a total of 291,707,120 shares[4] - The company reported a quarterly revenue of CNY 6,381,801,704.08 in Q4 2019, marking a steady growth throughout the year[21] - The net profit attributable to shareholders in Q4 2019 was CNY 80,304,831.27, showing a decline compared to previous quarters[21] - The pharmaceutical wholesale segment generated CNY 21,775.93 million, accounting for 98.15% of total revenue, with a growth of 23.51%[40] - Revenue from regions outside Beijing increased by 35.38% to CNY 12,952.19 million, while Beijing's revenue grew by 10.03% to CNY 9,234.39 million[41] - The company reported a profit distribution plan for 2019, proposing a cash dividend of 4.0 yuan per 10 shares, totaling 116,682,848.00 yuan, which represents 31.04% of the net profit attributable to shareholders[89] Asset Management and Financial Health - Cash and cash equivalents increased by 496.39 million, a growth of 45.96%, attributed to improved accounts receivable management[30] - Inventory rose by 529.44 million, a growth of 30.71%, driven by business expansion to support sales[30] - The company's accounts receivable at year-end was ¥6,938,116,218, which constituted 53.22% of total assets, a decrease of 4.17% from the previous year[63] - The total amount of financial assets at the end of the reporting period is 787,608.80 yuan, with no changes in fair value or impairment recorded during the period[65] - The company has no restricted asset rights as of the end of the reporting period[66] Business Expansion and Strategic Initiatives - The company maintained its position as a leading pharmaceutical distributor in Beijing while expanding its medical device and consumables services nationwide[27] - The company is actively exploring new business models, expanding from drug distribution to medical device supply chain services and hospital information services[31] - The company has strengthened its partnerships with upstream manufacturers, increasing the variety of products offered[31] - The company aims to explore online and offline business integration models to expand its internet business in response to the impact of internet healthcare on retail operations[80] - The company plans to enhance cooperation with hospitals and optimize personalized cooperation schemes to increase customer engagement and sales in the pharmaceutical sales sector[80] Investments and Acquisitions - The company acquired 51% of Beijing Jiashihui Medical Equipment Co., Ltd. for CNY 510,000 on January 31, 2019[46] - The company disposed of 51.08% of Shaanxi Jiashitang Pharmaceutical Co., Ltd. for CNY 19,079,300, effective December 31, 2019[47] - The company acquired 51% of Zhejiang Tonghuan Biotechnology Co., Ltd. for a cash consideration of RMB 43,758,000, with an outstanding payment of RMB 21,879,000 as of December 31, 2019[140] - The company purchased 51% of Zhejiang Jiashishangyang Medical Technology Co., Ltd. for RMB 61,200,000, with an unpaid amount of RMB 30,600,000 as of December 31, 2019[141] - The acquisition of 51% of Sichuan Jiashirongjin Pharmaceutical Co., Ltd. was completed for RMB 99,450,000, with an outstanding payment of RMB 14,708,400 as of December 31, 2019[142] Governance and Management - The company appointed Ernst & Young Hua Ming as its auditor for the 2019 fiscal year, with an audit fee of RMB 4.3 million[112] - The company has a diverse management team with extensive experience in various sectors, including pharmaceuticals and finance[179] - The company has implemented a remuneration adjustment plan approved by the shareholders' meeting to ensure competitive compensation for its executives[181] - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 837.96 million[183] - The highest remuneration was received by the chairman, Xu Wenli, totaling CNY 141.04 million[182] Corporate Social Responsibility - The company has invested 417.93 million CNY in poverty alleviation efforts, including 200 million CNY in healthcare resources for impoverished areas[136][137] - The company has supported the establishment of a medical assistance fund with an investment of 2 million CNY for congenital heart disease treatment in impoverished areas[135] - The company has mobilized 953 employees to donate over 60,000 CNY to support poverty alleviation initiatives[135] Compliance and Risk Management - The company emphasizes strict adherence to quality management and risk control, ensuring compliance with the "three major and one large" system for decision-making[86] - The company has not faced any penalties from securities regulatory authorities for its directors, supervisors, and senior management in the past three years[180] - The company has not reported any major environmental protection issues or status as a key pollutant discharge unit[139] Shareholder Structure and Ownership - The total number of ordinary shareholders at the end of the reporting period was 23,140, an increase from 21,885 at the end of the previous month[151] - The largest shareholder, China Youth Industrial Development Group, holds 14.36% of the shares, totaling 41,876,431 ordinary shares[152] - The actual controller of the company is China Everbright Group, which has a significant influence over various financial and non-financial sectors[155] - The total number of shares held by the top ten shareholders includes significant stakes from state-owned entities, indicating a strong government presence in the ownership structure[153]

Financial Performance - The company's operating revenue for 2019 was CNY 22,186,572,874.61, representing a 23.53% increase compared to CNY 17,959,885,466.92 in 2018[16] - The net profit attributable to shareholders for 2019 was CNY 375,957,176.99, which is a 14.75% increase from CNY 327,633,235.42 in the previous year[16] - The net cash flow from operating activities was CNY 293,114,556.75, a significant recovery from a negative cash flow of CNY -291,756,508.88 in 2018[16] - The total assets at the end of 2019 amounted to CNY 13,037,391,923.99, reflecting a 20.16% increase from CNY 10,850,365,413.55 at the end of 2018[17] - The net assets attributable to shareholders increased by 37.17% to CNY 3,425,524,154.59 from CNY 2,497,261,595.67 in 2018[17] - The basic earnings per share for 2019 were CNY 1.44, up 9.92% from CNY 1.31 in 2018[16] - The weighted average return on equity for 2019 was 13.38%, slightly down from 13.93% in 2018[16] - The company reported a quarterly revenue of CNY 6,381,801,704.08 in Q4 2019, marking a continuous growth trend throughout the year[21] - The net profit attributable to shareholders in Q4 2019 was CNY 80,304,831.27, showing a decline compared to previous quarters[21] Revenue Breakdown - The pharmaceutical wholesale segment generated CNY 21,775.93 million, accounting for 98.15% of total revenue, with a growth rate of 23.51%[40] - Revenue from regions outside Beijing increased by 35.38%, reaching CNY 12,952.19 million, while Beijing's revenue grew by only 10.03% to CNY 9,234.39 million[41] - The logistics segment's revenue increased by 24.75% to CNY 195.64 million, indicating strong growth in service capabilities[41] Inventory and Cash Management - Cash and cash equivalents increased by 496.39 million, a growth of 45.96%, attributed to improved accounts receivable management[30] - Inventory rose by 529.44 million, a growth of 30.71%, driven by business expansion to ensure sales[30] - The company reported a significant increase in inventory levels, with pharmaceutical wholesale inventory rising by 31.05% to CNY 2,214.50 million[44] - The company's accounts receivable at year-end was ¥6,938,116,218, which constituted 53.22% of total assets, a decrease of 4.17% from the previous year[63] - Inventory at year-end was ¥2,253,285,465, representing 17.28% of total assets, an increase of 1.39% due to business growth[63] Dividends and Profit Distribution - The company plans to distribute a cash dividend of CNY 4 per 10 shares, based on a total of 291,707,120 shares[4] - The company achieved a profit distribution plan for 2019, proposing a cash dividend of 4.0 yuan per 10 shares, totaling 116,682,848.00 yuan, which represents 31.04% of the net profit attributable to shareholders[89] - As of December 31, 2019, the company's distributable profits amounted to 1,048,000,053.53 yuan, showing a significant increase compared to previous years[89] Strategic Initiatives and Business Expansion - The company maintained its position as a leading pharmaceutical distributor in Beijing while expanding its medical device and consumables services nationwide[27] - The company is actively exploring new business models, expanding from drug distribution to medical device supply chain services and hospital information services[31] - The company has strengthened its cooperation with upstream manufacturers, leading to an increase in the variety of products offered[31] - The company aims to strengthen cooperation with hospitals and optimize personalized cooperation plans to increase customer engagement and enhance sales in the pharmaceutical sales sector[80] - The company plans to continue developing high-value consumables and maintain competitive advantages in the industry while promoting centralized distribution of consumables[81] - The company will explore the integration of online and offline business models to expand internet business in response to the impact of internet healthcare on retail operations[80] Corporate Governance and Management - The company has a diverse management team with extensive experience in various sectors, including pharmaceuticals and finance[177][178] - The board of directors includes independent directors who also receive remuneration from other affiliated entities[182] - The company emphasizes transparency in its remuneration policies, aligning them with shareholder interests[181] - The independent directors bring diverse expertise from various sectors, including finance and technology, which supports the company's governance and strategic direction[171] - The company is committed to maintaining high standards of corporate governance through the involvement of independent directors with significant industry experience[171] Financial Liabilities and Assets - The total amount of financial liabilities remains at 0.00 yuan, indicating no financial debt[65] - The total amount of financial assets at the end of the reporting period is 787,608.80 yuan, with no changes in fair value or impairment recorded during the period[65] - The company has no restricted asset rights as of the end of the reporting period[66] Employee and Community Engagement - The total number of employees in the company is 2,960, with 2,244 in major subsidiaries and 260 in the parent company[184] - The company has engaged 953 employees in charitable donations, raising over 60,000 CNY for the "Happiness Project - Rescue Poor Mothers Action"[135] - The company has established a special fund of 2 million CNY for medical assistance to children with congenital heart disease in impoverished areas[135] - The company has invested 417.93 million CNY in poverty alleviation efforts, including 200 million CNY specifically for healthcare resources in impoverished areas[136] Acquisitions and Investments - The company acquired 51% of Beijing Jiashi Weiye Medical Equipment Co., Ltd. for CNY 510,000, enhancing its market presence[46] - The company acquired 51% of Zhejiang Tonghuan Biotechnology Co., Ltd. for a cash consideration of RMB 43,758,000 on December 1, 2017, with an outstanding payment of RMB 21,879,000 as of December 31, 2019[140] - The company purchased 51% of Zhejiang Jiashishangyang Medical Technology Co., Ltd. for RMB 61,200,000, with an unpaid amount of RMB 30,600,000 as of December 31, 2019[141] - The acquisition of 51% of Sichuan Jiashirongjin Pharmaceutical Co., Ltd. was completed for RMB 99,450,000, with an outstanding payment of RMB 14,708,400 as of December 31, 2019[142] Regulatory Compliance and Reporting - The company adopted the new financial instrument standards starting January 1, 2019, which changed the classification and measurement of financial assets[98] - The company did not experience any major litigation or arbitration matters during the reporting period[115] - There were no significant penalties or rectification measures taken against the company during the reporting period[116] - The company has not faced any penalties from securities regulatory authorities in the past three years for its directors, supervisors, and senior management[180]

Financial Performance - The company's operating revenue for 2019 was CNY 22,186,572,874.61, representing a 23.53% increase compared to CNY 17,959,885,466.92 in 2018[16] - The net profit attributable to shareholders for 2019 was CNY 375,957,176.99, which is a 14.75% increase from CNY 327,633,235.42 in the previous year[16] - The net cash flow from operating activities for 2019 was CNY 293,114,556.75, a significant turnaround from a negative cash flow of CNY -291,756,508.88 in 2018[16] - The total assets at the end of 2019 amounted to CNY 13,037,391,923.99, reflecting a 20.16% increase from CNY 10,850,365,413.55 at the end of 2018[17] - The net assets attributable to shareholders increased by 37.17% to CNY 3,425,524,154.59 in 2019 from CNY 2,497,261,595.67 in 2018[17] - The basic earnings per share for 2019 was CNY 1.44, up 9.92% from CNY 1.31 in 2018[16] - The company reported a weighted average return on equity of 13.38% for 2019, slightly down from 13.93% in 2018[16] - The company achieved a net profit of ¥6.25 billion in 2019, a substantial increase from ¥3.94 billion in 2018, reflecting strong operational performance[24] - The net profit for 2019 was CNY 65,980,240, with a year-on-year growth of 15.63%[36] Revenue Breakdown - The pharmaceutical wholesale segment generated CNY 21,775,934,544.67, accounting for 98.15% of total revenue, with a growth of 23.51% compared to 2018[40] - Revenue from regions outside Beijing increased by 35.38%, reaching CNY 12,952,186,934.21, while Beijing's revenue grew by only 10.03%[41] - The fourth quarter revenue reached CNY 6,381,801,704.08, contributing significantly to the annual growth[21] Operational Changes and Strategies - The company has no significant changes in its main business since its listing, indicating stability in operations[15] - The company is actively exploring new business models, expanding from drug distribution to medical device supply chain services and hospital information services[31] - The company maintained its position as a leading pharmaceutical distributor in Beijing while expanding its medical device and consumables services nationwide[27] - The company is focusing on the development of high-value consumables and enhancing its competitive advantage in the industry[81] - The company is exploring online business models and enhancing its internet thinking to drive growth[82] Investments and Acquisitions - The company acquired 51% of Beijing Jiashihui Medical Equipment Co., Ltd. for CNY 510,000, expanding its market presence[46] - New subsidiaries were established in 2019, including Guangzhou Jiashixing Medical Technology Co., Ltd. and Zhejiang Jiashiqiantang Medical Equipment Co., Ltd., both focusing on medical device sales[49] - The company acquired 51% of Zhejiang Tonghan Biotechnology Co., Ltd. for RMB 43.76 million, with an outstanding payment of RMB 21.88 million as of December 31, 2019[140] - The company also acquired 51% of Zhejiang Jiashang Medical Technology Co., Ltd. for RMB 61.20 million, with an outstanding payment of RMB 30.60 million as of December 31, 2019[141] - The company purchased 51% of Sichuan Jiashirongjin Pharmaceutical Co., Ltd. for RMB 99.45 million, with an outstanding payment of RMB 14.71 million as of December 31, 2019[142] Cash Flow and Financial Management - Operating cash inflow totaled ¥24,592,375,383.27, a 24.69% increase compared to the previous year[54] - Cash and cash equivalents increased by ¥490,589,088.34, reflecting a growth of 1154.89% compared to the previous year[56] - The company's accounts receivable at year-end was ¥6,938,116,218.67, which decreased as a percentage of total assets by 4.17% due to improved collection efforts[63] - The company aims to reduce accounts receivable and inventory while improving operational efficiency through dedicated management[82] Shareholder Information - The company plans to distribute a cash dividend of CNY 4 per 10 shares, based on a total of 291,707,120 shares[4] - The company reported that its logistics business expansion did not meet expectations, leading to increased depreciation costs without significant scale effects[74] - The largest shareholder, China Youth Industry Development Group, holds 41,876,431 shares, representing 14.36% of total shares[152] - The actual controller of the company is China Everbright Group, which holds significant stakes in various financial institutions, including 46.45% in Everbright Securities[155] Corporate Governance and Management - The company has a structured management team with a mix of genders and ages[166] - The management team has a strong educational background, with many members holding advanced degrees, which contributes to informed decision-making[168][169][170] - The company has maintained a commitment to corporate governance, with independent directors actively participating in oversight roles[171] - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 955.61 million[183] Social Responsibility and Community Engagement - The company provided basic drug distribution services to 877 village clinics in Beijing's rural areas, ensuring access to essential medications[134] - The company invested a total of RMB 417.93 million in poverty alleviation efforts, including RMB 200 million in healthcare resources for impoverished areas[136] - The company engaged 953 employees in charitable donations, raising over 60,000 yuan for the "Happiness Project" to assist impoverished mothers[135]

Financial Performance - The company's operating revenue for 2019 was CNY 22,186,572,874.61, representing a 23.53% increase compared to CNY 17,959,885,466.92 in 2018[16] - The net profit attributable to shareholders for 2019 was CNY 375,957,176.99, which is a 14.75% increase from CNY 327,633,235.42 in the previous year[16] - The net cash flow from operating activities was CNY 293,114,556.75, a significant recovery from a negative cash flow of CNY -291,756,508.88 in 2018[16] - The total assets at the end of 2019 amounted to CNY 13,037,391,923.99, reflecting a 20.16% increase from CNY 10,850,365,413.55 at the end of 2018[17] - The net assets attributable to shareholders increased by 37.17% to CNY 3,425,524,154.59 from CNY 2,497,261,595.67 in 2018[17] - Basic earnings per share for 2019 were CNY 1.44, up 9.92% from CNY 1.31 in 2018[16] - The weighted average return on equity for 2019 was 13.38%, slightly down from 13.93% in 2018[16] - The company reported a net profit of ¥6.25 billion in 2019, a substantial increase from ¥3.94 billion in 2018, reflecting strong operational performance[24] Revenue and Sales Growth - The company reported a quarterly revenue of CNY 6,381,801,704.08 in Q4 2019, contributing to a total annual revenue growth[21] - The pharmaceutical wholesale segment generated CNY 21,775,934,544.67, accounting for 98.15% of total revenue, with a growth of 23.51% compared to 2018[40] - Revenue from regions outside Beijing increased by 35.38%, reaching CNY 12,952,186,934.21, while Beijing's revenue grew by only 10.03%[41] - The company maintained its position as a leading pharmaceutical distributor in Beijing while expanding its medical device and consumables services nationwide[27] Inventory and Cash Management - Cash and cash equivalents rose by ¥496.39 million, a 45.96% increase, attributed to improved management of accounts receivable[30] - Inventory levels increased by ¥529.44 million, a 30.71% rise, driven by business growth and the need to ensure product availability[30] - The company reported a significant increase in inventory levels, with pharmaceutical wholesale inventory rising by 31.05% to CNY 2,214,498,195.25[44] Investments and Acquisitions - The company acquired 51% of Beijing Jiashihui Medical Equipment Co., Ltd. for CNY 510,000, expanding its market presence[46] - New subsidiaries were established in 2019, including Guangzhou Jiashixing Medical Technology Co., Ltd. and Zhejiang Jiashiqiantang Medical Equipment Co., Ltd., both focusing on medical device sales[49] - The company acquired 51% of Zhejiang Tonghuan Biotechnology Co., Ltd. for a cash consideration of RMB 43,758,000, with an outstanding payment of RMB 21,879,000 as of December 31, 2019[141] - The company purchased 51% of Zhejiang Jiashi Shangyang Medical Technology Co., Ltd. for RMB 61,200,000, with an outstanding payment of RMB 30,600,000 as of December 31, 2019[142] - The acquisition of 51% of Chengdu Rongjin Pharmaceutical Trading Co., Ltd. was completed for RMB 99,450,000, with an outstanding payment of RMB 14,708,400 as of December 31, 2019[143] Corporate Governance and Management - The company has a diverse board of directors with various ages and backgrounds, ensuring a range of perspectives[166] - The management team includes a mix of experienced professionals, with the president being 48 years old[167] - The company has maintained a focus on significant projects and resource integration to support future business development[83] - The company is committed to complying with regulatory requirements regarding share lock-up periods[158] - The management team has extensive experience in the pharmaceutical industry, contributing to the company's strategic direction[181] Employee and Operational Structure - The total number of employees in the company is 2,960, with 2,244 in major subsidiaries and 260 in the parent company[185] - The professional composition includes 442 production personnel, 2,079 sales personnel, 53 technical personnel, 183 financial personnel, and 203 administrative personnel[185] - The company has established effective performance evaluation and incentive mechanisms, which are being gradually improved[191] - The company has a complete and independent supply chain system, ensuring its ability to operate autonomously in the market[193] Risk Management and Compliance - The company emphasizes risk control and compliance, enhancing operational auditing and accounts receivable management to mitigate business risks[28] - The company has committed to strict financial management and quality control, adhering to the "three major and one large" system[83] - The company has not reported any significant impact from the exit of its equity investment in Shaanxi Jiashitang Pharmaceutical Co., Ltd.[79] Shareholder Information - The largest shareholder, China Youth Industrial Development Group, holds 41,876,431 shares, representing 14.36% of total shares[152] - The second largest shareholder, China Everbright Group, holds 41,180,800 shares, representing 14.12% of total shares[152] - The company has a total of 23,140 shareholders at the end of the reporting period[153] - The actual controller, China Everbright Group, holds significant stakes in various listed companies, including 46.45% in Everbright Securities[156] Profit Distribution - The company reported a profit distribution plan for 2019, proposing a cash dividend of 4.0 yuan per 10 shares, totaling 116,682,848.00 yuan, which represents 31.04% of the net profit attributable to shareholders[90] - As of December 31, 2019, the company's distributable profits amounted to 1,048,000,053.53 yuan, showing an increase from 896,985,713.36 yuan in 2018[90] Community Engagement and Social Responsibility - The company has invested 417.93 million CNY in poverty alleviation efforts, including 200 million CNY specifically for healthcare resources in impoverished areas[136] - The company has established a "Angel Medical Assistance Fund" with an investment of 2 million CNY to support children with congenital heart disease in impoverished areas[136] - The company has mobilized 953 employees to donate over 60,000 CNY to the "Happiness Project - Rescue Poor Mothers Action"[136]

Financial Performance - Operating revenue for the current period was CNY 5.57 billion, up 19.86% year-on-year[7] - Net profit attributable to shareholders for the current period was CNY 84.32 million, an increase of 12.75% year-on-year[7] - Total operating revenue for Q3 2019 reached CNY 5,566,019,067.11, an increase of 19.88% compared to CNY 4,643,590,103.16 in the same period last year[34] - The company's net profit for the period was not explicitly stated, but the increase in total revenue and costs suggests a focus on growth despite rising expenses[34] - Net profit for Q3 2019 reached CNY 157,515,495.52, an increase of 12.5% compared to CNY 140,279,988.08 in Q3 2018[36] - The company reported a total profit of CNY 213,381,002.79 for Q3 2019, up from CNY 189,766,675.71 in Q3 2018, marking an increase of 12.5%[35] - The company reported a total profit of CNY 687,120,737.38 for Q3 2019, up from CNY 604,496,213.64 in the previous year, marking an increase of 13.7%[43] Assets and Liabilities - Total assets increased by 13.80% to CNY 12.35 billion compared to the end of the previous year[7] - The company's total assets reached CNY 12.35 billion, up from CNY 10.85 billion at the beginning of the year[25] - Total liabilities as of September 30, 2019, were CNY 7,528,698,231.85, compared to CNY 7,117,660,487.90 at the end of 2018, showing a growth in leverage[27] - Total equity attributable to shareholders rose to CNY 3,340,584,942.83 from CNY 2,497,261,595.67, marking a significant increase of 33.83%[27] - Total liabilities to equity ratio stands at approximately 1.91, indicating a leveraged capital structure[60] Cash Flow - Net cash flow from operating activities surged by 339.74% to CNY 268.65 million compared to the same period last year[7] - The company's net cash flow from operating activities increased by CNY 801.55 million, a growth of 185.23%, attributed to enhanced receivables management and negotiations with suppliers[15] - Operating cash inflow for the third quarter was CNY 18.02 billion, an increase from CNY 14.29 billion in the same period last year, representing a growth of approximately 26.5%[50] - Net cash flow from operating activities was CNY 368.83 million, a significant recovery from a negative cash flow of CNY 432.72 million in the previous year[50] Shareholder Information - The total number of shareholders at the end of the reporting period was 22,232[11] - The largest shareholder, China Youth Industrial Development Corporation, holds 16.72% of the shares[11] Expenses and Costs - Sales expenses increased by CNY 205.02 million, a growth of 51.94%, due to changes in business structure and increased employee wages[15] - Total operating costs amounted to CNY 5,347,004,357.04, up from CNY 4,441,291,982.18, reflecting a year-over-year increase of 20.41%[34] - The company reported a decrease in investment income by CNY 0.95 million, a decline of 87.66%, primarily due to reduced income from structured deposits[15] Inventory and Receivables - Accounts receivable increased by CNY 2,025.34 million, a growth of 40.09%, mainly due to the adjustment of accounts receivable from the early termination of ABN asset-backed notes[15] - Inventory levels remained stable with a slight decrease to CNY 457,856,289.69 from CNY 461,134,711.90, indicating effective inventory management[30] Research and Development - Research and development expenses were not explicitly detailed but are critical for future product development and market expansion strategies[38] - Research and development expenses were CNY 21,287,636.25, reflecting the company's commitment to innovation and product development[46] Future Outlook - The company plans to continue its market expansion and product development initiatives to sustain growth in the upcoming quarters[38] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[46] Miscellaneous - The company reported no significant non-recurring gains or losses during the reporting period[9] - The third quarter report was not audited[65] - The company is under the new financial instrument standards since 2019[65] - The report was presented by Chairman Xu Wenli on October 17, 2019[66]

Financial Performance - The company's operating revenue for the first half of 2019 was ¥10,238,752,103.42, representing a 20.17% increase compared to ¥8,519,990,778.55 in the same period last year[17]. - The net profit attributable to shareholders of the listed company was ¥211,329,772.79, up 13.98% from ¥185,402,548.02 in the previous year[17]. - Basic earnings per share increased to ¥0.84, reflecting a 13.51% rise from ¥0.74 in the previous year[17]. - The company reported a net profit for the first half of 2019 of ¥351,884,054.64, representing a 13.7% increase from ¥309,422,152.52 in the first half of 2018[133]. - The net profit attributable to the parent company was 21,132.98 million RMB, reflecting a growth of 13.98% year-on-year[31]. Cash Flow - The net cash flow from operating activities was ¥100,178,639.62, a significant recovery from a negative cash flow of -¥320,663,589.17 in the same period last year, marking a 131.24% improvement[17]. - The company reported a significant improvement in cash flow from operating activities, generating ¥100,178,639.62 compared to a negative cash flow of -¥320,663,589.17 in the previous year[36]. - Cash inflow from operating activities reached CNY 11,768,152,348.62, an increase of 33.5% from CNY 8,838,477,884.62 in the previous year[139]. - The net cash flow from financing activities was CNY 47,400,468.27, a decrease of 92.9% compared to CNY 669,118,160.49 in the first half of 2018[142]. Assets and Liabilities - Total assets at the end of the reporting period were ¥11,808,806,914.51, an 8.83% increase from ¥10,850,365,413.55 at the end of the previous year[17]. - Total liabilities amounted to CNY 7.74 billion, up from CNY 7.12 billion, indicating an increase of 8.7%[125]. - The total liabilities at the end of the reporting period were CNY 1,115.60 million, which is an increase from CNY 989.97 million at the beginning of the year, indicating a rise of about 12.7%[152]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,442[105]. - The largest shareholder, China Youth Industry Development Corporation, holds 16.72% of the shares, totaling 41,876,431 shares[105]. - The company has a total of 250,526,315 shares, with 99.46% being unrestricted shares[103]. Business Operations and Strategy - The company optimized its business structure and product layout, enhancing the quality of operations and reducing business risks[26]. - The company established a new logistics center in Hebei to enhance service capabilities in the Beijing-Tianjin-Hebei region[33]. - The company is focusing on enhancing cash management and exploring financing options to address increasing capital demands due to business expansion[63]. - The company aims to enhance its market presence and product offerings through strategic investments and potential acquisitions in the future[141]. Social Responsibility - The company actively participated in social responsibility initiatives, including poverty alleviation efforts and community healthcare support[90]. - The company has invested a total of RMB 126 million in poverty alleviation efforts, including RMB 120 million in direct donations to support targeted poverty alleviation in three counties in Hunan Province[92]. - The company has established a special fund of RMB 1 million for medical assistance, specifically targeting congenital heart disease in children from impoverished mountainous areas[92]. Risk Management - The company emphasized risk management and control, enhancing its risk prevention capabilities[32]. - The company faces risks from policy changes in the medical reform landscape, impacting drug and medical consumable pricing, which may affect revenue growth[63]. - The company is expanding its national pharmaceutical sales network through acquisitions, adapting strategies to local market conditions to mitigate cross-regional operational risks[64]. Accounting and Compliance - The financial statements prepared by the company comply with the accounting standards and accurately reflect its financial position, operating results, and cash flows[167]. - The company adopts Renminbi as its accounting currency[170]. - The company follows specific accounting policies and estimates tailored to its operational characteristics[166].

证券代码：002462 证券简称：嘉事堂 公告编号：2019-临 056 嘉事堂药业股份有限公司 关于参加北京辖区深市上市公司投资者集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与广大投资者的沟通交流,嘉事堂药业股份有限公司(以下简 称"公司")将参加由北京上市公司协会、深圳全景网络有限公司共同举办的"2019 年北京辖区深市上市公司投资者集体接待日"活动,现将有关事项公告如下: 本次活动将在深圳市全景网络有限公司提供的网上平台,采取网络远程的方 式举行。活动时间为2019年7月18日(星期四)15：00-17：00。投资者可登陆"全 景路演天下"参与本次互动交流(http://rs。p5w。net/htm1/103630。shtm1), 或扫描二维码方式登录参与。 届时公司董事长续文利先生、总裁许帅先生、副总裁兼董事会秘书王新侠女 士将通过网络在线形式与投资者就公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关注的问题进行沟通。 欢迎广大投资者积极参与。 嘉事堂药业股份有限公司 董事会 2019 年 ...